Unifarco closes 2024 with revenues of EUR 182.9 million (+10.5%)

Unifarco - a company from Belluno that operates in the health and wellness sector in pharmacies with brands such as Ceramol, Biomalife and Dolomia - closed 2024 with a turnover of 182.9 million euro, up 10.5% compared to the previous year. Ebitda stood at EUR 27.7 million.

Double-digit growth in all European markets thanks to the export of its business model, adapted to the peculiarities of individual countries. In particular, the results of the community brand Farmacisti Preparatori and of the proprietary brands present abroad are worth highlighting, with growth in Spain of 21%, in Germany of 15.6%, in France - where the Unifarco France sales subsidiary was launched in 2024 - and Belgium of 18.1% and in Austria of 17.1%.

Positive signs also for all group brands: Farmacisti Preparatori, cosmetics and supplements signed by individual pharmacies, recorded 111.9 million in consolidated turnover in 2024, up 6.1% compared to the previous year; Ceramol - dermatological products and medical devices dedicated to the treatment of certain specific skin dysfunctions - grew by 19.1%; Biomalife - the first line of dietary supplements specifically for restoring and maintaining the wellbeing of the intestinal barrier - recorded +76.7%; Dolomia - skin care and make-up using extracts from nature in the Dolomites to combat stress, pollution and skin ageing - closed 2024 with sales in line with the previous year; MyCli - a complete range of cosmeceuticals and nutritional supplements developed thanks to strong expertise in the field of aesthetic medicine to stimulate and defend the skin's self-correction processes - closes the year with revenues of +24.3%; Keylife - a brand that offers low-carb, anti-inflammatory diet protocols and for the control of metabolic parameters - continues with the path of strong development started in previous years, closing the year with a 12% growth; Genage - a brand born from the collaboration with Metodo Ongaro Switzerland (today Swiss Longevity Solutions) and with international doctors, geneticists and researchers - registers a 28.1% increase compared to the previous year.

During the year, the numerous activities in the Research and Development area continued, also through collaborations with prestigious research bodies, with the aim of always proposing cutting-edge, safe and effective solutions so that pharmacists can take care of people by providing authoritative personalised advice and offering products and services with a high scientific value. In this regard, it should be noted that at a consolidated level, total investment in the scientific field exceeds 5 million Euro, equal to 2.9% of sales revenue.

With more than 6,500 customer pharmacies in Europe and around 360 member pharmacists, Unifarco is aiming for further growth with investments of EUR 16 million in 2024.